CD47 mAb TJ011133 (TJC4, Lemzoparlimab) is being tested in a phase I trial for R/R AML or MDS, showing promising efficacy and manageable adverse events (NCT04202003). The gene discussed is CD47; the disease is acute myeloid leukemia.